A Brief Overview of Global Trends in MSC-Based Cell Therapy

Overview

Journal Stem Cell Rev Rep

Publisher Springer

Specialty Cell Biology

Date 2022 Mar 28

PMID 35344199

Authors

Dragomirka Jovic

Yingjia Yu

Dan Wang

Kuixing Wang

Hanbo Li

Fengping Xu

Chenglong Liu

Junnian Liu

Yonglun Luo

Affiliations

Soon will be listed here.

Abstract

Human mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells or medicinal signaling cells, are important adult stem cells for regenerative medicine, largely due to their regenerative characteristics such as self-renewal, secretion of trophic factors, and the capability of inducing mesenchymal cell lineages. MSCs also possess homing and trophic properties modulating immune system, influencing microenvironment around damaged tissues and enhancing tissue repair, thus offering a broad perspective in cell-based therapies. Therefore, it is not surprising that MSCs have been the broadly used adult stem cells in clinical trials. To gain better insights into the current applications of MSCs in clinical applications, we perform a comprehensive review of reported data of MSCs clinical trials conducted globally. We summarize the biological effects and mechanisms of action of MSCs, elucidating recent clinical trials phases and findings, highlighting therapeutic effects of MSCs in several representative diseases, including neurological, musculoskeletal diseases and most recent Coronavirus infectious disease. Finally, we also highlight the challenges faced by many clinical trials and propose potential solutions to streamline the use of MSCs in routine clinical applications and regenerative medicine.

Citing Articles

Comparative Study of Deep Transfer Learning Models for Semantic Segmentation of Human Mesenchymal Stem Cell Micrographs.

Solopov M, Chechekhina E, Kavelina A, Akopian G, Turchin V, Popandopulo A Int J Mol Sci. 2025; 26(5).

PMID: 40076956 PMC: 11899854. DOI: 10.3390/ijms26052338.

Stem cell therapy: A promising therapeutic approach for skeletal muscle atrophy.

Wang Y, Chen Z, Shen Y, Wang K, Han Y, Zhang C World J Stem Cells. 2025; 17(2):98693.

PMID: 40061264 PMC: 11885941. DOI: 10.4252/wjsc.v17.i2.98693.

Application of mesenchymal stem cells in liver fibrosis and regeneration.

Liu Z, Ren J, Qiu C, Wang Y, Zhang T Liver Res. 2025; 8(4):246-258.

PMID: 39958916 PMC: 11771278. DOI: 10.1016/j.livres.2024.11.004.

The role of GATA4 in mesenchymal stem cell senescence: A new frontier in regenerative medicine.

Babu M, S R, Kaur I, Kumar S, Sharma N, Kumar M Regen Ther. 2025; 28():214-226.

PMID: 39811069 PMC: 11731776. DOI: 10.1016/j.reth.2024.11.017.

Immortalization of Mesenchymal Stem Cells for Application in Regenerative Medicine and Their Potential Risks of Tumorigenesis.

Yamaguchi N, Horio E, Sonoda J, Yamagishi M, Miyakawa S, Murakami F Int J Mol Sci. 2025; 25(24.

PMID: 39769322 PMC: 11676347. DOI: 10.3390/ijms252413562.

References

de Wert G, Mummery C . Human embryonic stem cells: research, ethics and policy. Hum Reprod. 2003; 18(4):672-82. DOI: 10.1093/humrep/deg143. View

Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4):663-76. DOI: 10.1016/j.cell.2006.07.024. View

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K . Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131(5):861-72. DOI: 10.1016/j.cell.2007.11.019. View

Yamanaka S . Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges. Cell Stem Cell. 2020; 27(4):523-531. DOI: 10.1016/j.stem.2020.09.014. View

Fu X, Xu Y . Challenges to the clinical application of pluripotent stem cells: towards genomic and functional stability. Genome Med. 2012; 4(6):55. PMC: 3698533. DOI: 10.1186/gm354. View

Quinlan A, Boland M, Leibowitz M, Shumilina S, Pehrson S, Baldwin K . Genome sequencing of mouse induced pluripotent stem cells reveals retroelement stability and infrequent DNA rearrangement during reprogramming. Cell Stem Cell. 2011; 9(4):366-73. PMC: 3975295. DOI: 10.1016/j.stem.2011.07.018. View

Laurent L, Ulitsky I, Slavin I, Tran H, Schork A, Morey R . Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell. 2011; 8(1):106-18. PMC: 3043464. DOI: 10.1016/j.stem.2010.12.003. View

Liu X, Li W, Fu X, Xu Y . The Immunogenicity and Immune Tolerance of Pluripotent Stem Cell Derivatives. Front Immunol. 2017; 8:645. PMC: 5454078. DOI: 10.3389/fimmu.2017.00645. View

Yoshihara M, Oguchi A, Murakawa Y . Genomic Instability of iPSCs and Challenges in Their Clinical Applications. Adv Exp Med Biol. 2020; 1201:23-47. DOI: 10.1007/978-3-030-31206-0_2. View

10.

Zhao T, Zhang Z, Rong Z, Xu Y . Immunogenicity of induced pluripotent stem cells. Nature. 2011; 474(7350):212-5. DOI: 10.1038/nature10135. View

11.

Ben-David U, Benvenisty N . The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer. 2011; 11(4):268-77. DOI: 10.1038/nrc3034. View

12.

Ferrari G, Thrasher A, Aiuti A . Gene therapy using haematopoietic stem and progenitor cells. Nat Rev Genet. 2020; 22(4):216-234. DOI: 10.1038/s41576-020-00298-5. View

13.

Wilkinson A, Igarashi K, Nakauchi H . Haematopoietic stem cell self-renewal in vivo and ex vivo. Nat Rev Genet. 2020; 21(9):541-554. PMC: 7894993. DOI: 10.1038/s41576-020-0241-0. View

14.

Laurenti E, Gottgens B . From haematopoietic stem cells to complex differentiation landscapes. Nature. 2018; 553(7689):418-426. PMC: 6555401. DOI: 10.1038/nature25022. View

15.

Feige P, Brun C, Ritso M, Rudnicki M . Orienting Muscle Stem Cells for Regeneration in Homeostasis, Aging, and Disease. Cell Stem Cell. 2018; 23(5):653-664. PMC: 6262894. DOI: 10.1016/j.stem.2018.10.006. View

16.

Judson R, Rossi F . Towards stem cell therapies for skeletal muscle repair. NPJ Regen Med. 2020; 5:10. PMC: 7214464. DOI: 10.1038/s41536-020-0094-3. View

17.

Zuk P, Zhu M, Mizuno H, Huang J, Futrell J, Katz A . Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001; 7(2):211-28. DOI: 10.1089/107632701300062859. View

18.

Fei X, Jiang S, Zhang S, Li Y, Ge J, He B . Isolation, culture, and identification of amniotic fluid-derived mesenchymal stem cells. Cell Biochem Biophys. 2013; 67(2):689-94. DOI: 10.1007/s12013-013-9558-z. View

19.

Gartner S, Kaplan H . Long-term culture of human bone marrow cells. Proc Natl Acad Sci U S A. 1980; 77(8):4756-9. PMC: 349925. DOI: 10.1073/pnas.77.8.4756. View

20.

Peng Y, Ke M, Xu L, Liu L, Chen X, Xia W . Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation. 2012; 95(1):161-8. DOI: 10.1097/TP.0b013e3182754c53. View